58,354 Shares in Stryker Corporation (SYK) Acquired by Moody Lynn & Lieberson LLC
Moody Lynn & Lieberson LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 58,354 shares of the medical technology company’s stock, valued at approximately $8,287,000.
Other hedge funds have also bought and sold shares of the company. Coldstream Capital Management Inc. increased its holdings in Stryker Corporation by 3.7% during the 2nd quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock worth $2,421,000 after purchasing an additional 626 shares during the last quarter. Lockheed Martin Investment Management Co. bought a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $1,249,000. Toronto Dominion Bank increased its holdings in shares of Stryker Corporation by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock valued at $14,625,000 after acquiring an additional 21,585 shares during the last quarter. Colonial Trust Advisors increased its holdings in shares of Stryker Corporation by 56.1% in the 2nd quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after acquiring an additional 8,426 shares during the last quarter. Finally, JLB & Associates Inc. bought a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $5,090,000. Institutional investors own 74.15% of the company’s stock.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.40% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada reiterated a “buy” rating and issued a $155.00 price target on shares of Stryker Corporation in a report on Monday, October 2nd. Oppenheimer Holdings, Inc. set a $156.00 price target on Stryker Corporation and gave the company a “hold” rating in a report on Monday, October 30th. BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Robert W. Baird reiterated a “hold” rating and issued a $161.00 price target on shares of Stryker Corporation in a report on Friday, October 27th. Finally, Cowen and Company set a $166.00 price target on Stryker Corporation and gave the company a “buy” rating in a report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have given a buy rating to the company’s stock. Stryker Corporation presently has an average rating of “Hold” and an average target price of $151.52.
Shares of Stryker Corporation (NYSE:SYK) traded down $2.14 during mid-day trading on Monday, reaching $154.48. The company’s stock had a trading volume of 1,267,200 shares, compared to its average volume of 1,183,556. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. Stryker Corporation has a one year low of $106.48 and a one year high of $160.62. The firm has a market cap of $58,100.00, a price-to-earnings ratio of 24.48, a PEG ratio of 2.43 and a beta of 0.79.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The company’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.39 earnings per share. analysts predict that Stryker Corporation will post 6.47 EPS for the current year.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.